검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Sargramostim (GM-CSF) |
Overview Company | Bionor Immuno AS |
Overview Modality | ANTIBODY |
Overview Target | Unresectable Melanoma |
Overview Indication | Unresectable Melanoma; Metastatic Melanoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeting CD16 and the epidermal growth factor receptor |
MoA Biomarker | biomarkers to support personalized treatment strategies |
PK/PD Half-life | 1.4 h |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | Neutrophil elastase-SERPINB1 axis in epithelial responses: Cell death, inflammation and SERPINB1 dynamics.. Chronic inflammatory lung diseases are associated with elevated levels of neutrophil elastase (NE), leading to epithelial damage and dysregulated cellular responses. However, the molecular mechanisms underlying NE-mediated disruption of epithelial anti-protease defenses, including the regula… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 67% |
Clinical ORR | 67% |
Clinical PFS | 10.8 |
Clinical OS | 10.8 |
Clinical Result source | ClinicalTrials.gov NCT04314843 |
Clinical Data Tier / Score | A · 45 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Sargramostim (GM-CSF) |
Overview Company | Bionor Immuno AS |
Overview Modality | ANTIBODY |
Overview Target | Unresectable Melanoma |
Overview Indication | Unresectable Melanoma; Metastatic Melanoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeting CD16 and the epidermal growth factor receptor |
MoA Biomarker | biomarkers to support personalized treatment strategies |
PK/PD Half-life | 1.4 h |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | Neutrophil elastase-SERPINB1 axis in epithelial responses: Cell death, inflammation and SERPINB1 dynamics.. Chronic inflammatory lung diseases are associated with elevated levels of neutrophil elastase (NE), leading to epithelial damage and dysregulated cellular responses. However, the molecular mechanisms underlying NE-mediated disruption of epithelial anti-protease defenses, including the regula… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 67% |
Clinical ORR | 67% |
Clinical PFS | 10.8 |
Clinical OS | 10.8 |
Clinical Result source | ClinicalTrials.gov NCT04314843 |
Clinical Data Tier / Score | A · 45 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교